3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia
1
Hematologic Neoplasms
1
Interventions
Rituximab
4
ibrutinib
2
fludarabine phosphate
2
fludarabine
2
blinatumomab
2
Vorinostat
2
Radiation
2
Nivolumab
2
Lenalidomide
2
Gemcitabine
2
Cytarabine
2
Cyclophosphamide
2
CT-P10
2
umbralisib
1
ublituximab
1
tafasitamab
1
polatuzumab vedotin
1
pembrolizumab
1
ofatumumab
1
molibresib
1
magrolimab
1
iberdomide
1
glofitamab
1
entinostat
1
cirmtuzumab
1
carmustine, poliferprosan 20 drug combination
1
asparaginase erwinia chrysanthemi recombinant
1
X-Rays
1
Tacrolimus
1
Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, B-Cell
×
ofatumumab
×
Clear all
NCT00093314
2015-04-21
HuMax-CD20 in Chronic Lymphocytic Leukemia
GlaxoSmithKline
Phase 1/2
Withdrawn